Alcon Laboratories, Inc.

Alcon Universal Ltd.

Alcon, Inc.

Alcon Manufacturing, Ltd.

Novartis Ag

Gustav Graff

Mark R Hellberg

John M Yanni

Peter G Klimko

Daniel A Gamache

Jon C Nixon

Mutlu Karakelle

Bhagwati P Kabra

Michael A Kapin

William H Garner

John W Sheets, Jr

David Allen Marsh

Karen C David

Youqin Tian

Janet D Howie

Timothy L Kessler

Wiliam H Garner

Drug delivery film compositions containing a combination of a water-soluble, film-forming polymers and a fatty acid glyceride or ester are suitable for delivering ophthalmic drugs.

Bioerodible film for ophthalmic drug delivery

Ophthalmic compositions containing Lipoxin A and its analogs and methods of their use for treating dry eve are disclosed.

Lipoxin A4 and its analogs for the treatment of dry eye

The topical use of certain flurbiprofen amide derivatives and ketorolac amide derivatives to treat ophthalmic angiogenesis-related and inflammatory disorders of the posterior segment of the eye is disclosed.

Method of treating ocular inflammatory and angiogenesis-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolac

The use of 3-benzolphenylacetic acids and derivatives, including nepafenac, to treat neurodegenerative retinal disorders is disclosed.

Method of treating neurodegenerative disorders of the retina and optic nerve head

Phospholipid-HETE derivatives, compositions and methods of use are disclosed. The compounds are particularly useful for treating dry eye.

Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use

3-heteroatom substituted and two carbon homologs of 15-HETE, and their derivatives, compositions and methods of their use for treating dry eye are disclosed.

3-heteroatom substituted and two carbon homologs of 15-HETE and methods of use

Methods for treating post-surgical formation of cataracts or posterior capsule opacification are disclosed. The methods utilize compositions containing certain compounds having an anti-inflammatory and anti-oxidant moiety covalently linked by and amide and ester bond.

Methods for the prevention and treatment of post-surgical complications

Topical ophthalmic anti-allergy drugs are identified by the extent of their interaction with a phospholipid model membrane. Disclosed are topically administrable ophthalmic formulations containing amphipathic anti-allergy compounds at concentrations such that the drugs have Surface Activity Ratings from about 2-11.

Topical ophthalmic mast cell stabilizers for treating allergic eye disease

This invention relates to the compositions and methods for the treatment of corneal haze. The compositions and methods are particularly directed to the use of GAG synthesis inhibitors in the treatment of corneal haze.

Use of inhibitors of gag synthesis for the treatment of corneal haze

HETE derivatives and methods of their use for treating dry eye are disclosed.

15-Hydroxyeicosatetraenoic acid-related compounds and methods of use

Compounds having ant-inflammatory and anti-oxidant activity are disclosed. The compounds are useful in preventing and treating inflammatory disorders through several mechanisms. Methods of treatment employing these properties of the compounds and corresponding pharmaceutical composition are disclosed.

Ophthalmic viscoelastic compositions

An improved model of endotoxin-induced inflammation is obtained by eliminating the interference in the biochemical assay of myeloperoxidase caused by endogenous reductants and cellular constituents containing free thiol functional groups. The interference was eliminated by 1) extensively diluting soluble, interfering substances and 2) blocking tissue sulfhydril functional groups during tissue homogenization. The improved model can be used to assess the therapeutic potential of anti-inflammatory agents. For example, the model can be used to evaluate topically administrable ophthalmic anti-inflammatory agents in Lewis rats.

Growing community of inventors

Cleburne, TX, United States of America

Gustav Graff